[Partnership between academic research and industry to study a new anti-osteoporotic drug].
The activity of the osteoclast, the cell responsible for bone resorption, is subjected to different regulation factors. Amongst these, those issued from the matrix, particularly released minerals such as calcium, are determinants. We have shown that variations in calcium concentration in the medium regulates resorption activity and duration of the osteoclast lifespan. The development of a new therapeutic agent, strontium ranelate, has shown very interesting clinical effects reliant on the stimulation of bone formation activity by osteoblasts and modulation of bone resorption activity. From our knowledge regarding osteoclast physiology, in particular calcium signaling pathways, and the control of different osteoclast cellular models, a consequent collaboration was formed between our laboratory and Servier in order to elaborate on the effects of strontium ranelate on the osteoclast. In several years, this collaboration has been further enriched by other collaborators in order to better understand this mechanism. It has also been shown that strontium likely interacts with the calcium-sensing receptor and that the pathways of intracellular signaling pathways activated by calcium and strontium ranelate via this receptor are different. In fact, within the scope of this collaboration with Servier, exchanges with other academic laboratories were initiated and collaboration on numerous techniques became possible. Then, it has been possible to confirm the presence of the calcium-sensing receptor on the osteoclasts and to demonstrate its role in the molecular events associated with strontium ranelate's effects on the osteoclast.
Unité de Recherche des mécanismes de la résorption osseuse, Faculté de Pharmacie, Amiens, France.
Romuald
R
Mentaverri
Alice
A
Wattel
Anne-Sophie
AS
Lemaire-Hurtel
Said
S
Kamel
Alexia
A
Blesius
Michel
M
Brazier
D000818:Animals; D001862:Bone Resorption / Q000517:prevention & control; D002118:Calcium / Q000502:physiology; D015195:Drug Design; D006801:Humans; D007221:Industry; D007373:Interinstitutional Relations; D010010:Osteoclasts / Q000473:pathology / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D012106:Research
D002118:Calcium